gene

CAV1

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about CAV1: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

503Connections

0Hypotheses

1Analyses

50Outgoing

50Incoming

0Experiments

1Debates

Summary

CAV1 is a gene implicated in neurodegeneration research. Key relationships include: activates, associated with, expressed in. Associated with ALS, Als, Alzheimer. Connected to 119 entities in the SciDEX knowledge graph.

View on Wiki →

No AI portrait yet

🧬 Gene Info

Gene Symbol	CAV1
Aliases	Caveolin 1, Caveolin-1
Protein Type	Structural Protein
Target Class	Structural Protein
Function	No established drugging mechanism for structural membrane protein
Mechanism of Action	No established drugging mechanism for structural membrane protein
Druggability	Low (0.35)
Clinical Stage	Approved
Molecular Weight	22 kDa
Pathways	MAPK pathway, PI3K
UniProt ID	Q2TNI1
GeneCards	CAV1
Human Protein Atlas	CAV1
Associated Diseases	Als, Alzheimer, Anxiety, atherosclerosis
Known Drugs/Compounds	Daidzein
Interactions	ABCB1, Actin, ADAMTS1, Adiponectin, AGO2, Akt
SciDEX Target	View Target Profile (1 clinical trials)
KG Connections	503 knowledge graph edges
Databases	GeneCards NCBI Gene HPA STRING

🔮 Predicted Structure: CAV1 — AlphaFold Q2TNI1 Click to expand

AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (4)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

graph TD
    CAV1["CAV1"] -->|"associated"| neurodegeneration["neurodegeneration"]
    CAV1["CAV1"] -->|"interacts"| TFR1["TFR1"]
    CAV1["CAV1"] -->|"interacts"| LRP1["LRP1"]
    CAV1["CAV1"] -->|"interacts"| ABCB1["ABCB1"]
    CAV1["CAV1"] -->|"co discussed"| ABCB1_1["ABCB1"]
    CAV1["CAV1"] -->|"co discussed"| FCGRT["FCGRT"]
    TFR1_2["TFR1"] -->|"interacts"| CAV1["CAV1"]
    LRP1_3["LRP1"] -->|"interacts"| CAV1["CAV1"]
    ABCB1_4["ABCB1"] -->|"interacts"| CAV1["CAV1"]
    LRP1_5["LRP1"] -->|"co discussed"| CAV1["CAV1"]
    style CAV1 fill:#4a1a6b,stroke:#4fc3f7,stroke-width:2px,color:#e0e0e0

Outgoing (367)

Target	Relation	Type	Str
Cytosolic CLDN5 Aggregation	causes	phenotype	0.90
CLDN5	mediates	protein	0.90
Blood-Brain Barrier Disruption	contributes_to	phenotype	0.87
BACE1	modulates	protein	0.85
CLDN5 Redistribution	mediates	process	0.85
Retinal Ganglion Cell Senescence	upregulates	process	0.85
CLDN5	regulates	gene	0.85
Retinal Ganglion Cell Senescence	mediates	process	0.85
endothelial barrier integrity	regulates	process	0.80
caveolin_1	encodes	protein	0.80
interstitial fibrosis and tubular atrophy	associated_with	phenotype	0.75
oxidative stress response	participates_in	pathway	0.70
Als	expressed_in	disease	0.65
Infection	associated_with	disease	0.65
Alzheimer	associated_with	disease	0.65
Als	associated_with	disease	0.65
Als	therapeutic_target	disease	0.65
Anxiety	associated_with	disease	0.65
Tumor	expressed_in	disease	0.65
Als	activates	disease	0.65
Parkinson	therapeutic_target	disease	0.65
Ms	expressed_in	disease	0.65
Ms	regulates	disease	0.65
Cancer	expressed_in	disease	0.65
Glaucoma	causes	disease	0.65
Inflammation	associated_with	disease	0.65
Cancer	associated_with	disease	0.65
Alzheimer	therapeutic_target	disease	0.65
Ms	causes	disease	0.65
Als	causes	disease	0.65
Stroke	activates	disease	0.65
ALS	expressed_in	disease	0.65
Cancer	activates	disease	0.65
ALS	activates	disease	0.65
Tumor	activates	disease	0.65
Neurodegeneration	contributes_to	disease	0.65
Leukemia	activates	disease	0.65
Carcinoma	activates	disease	0.65
Aging	contributes_to	disease	0.65
Parkinson	contributes_to	disease	0.65
ALS	regulates	disease	0.65
ALS	interacts_with	disease	0.65
Diabetes	associated_with	disease	0.65
Ms	associated_with	disease	0.65
Fibrosis	activates	disease	0.65
Cancer	therapeutic_target	disease	0.65
Cancer	interacts_with	disease	0.65
Atherosclerosis	associated_with	disease	0.65
Als	regulates	disease	0.65
Neurodegeneration	regulates	disease	0.65

Incoming (136)

Source	Relation	Type	Str
AUTOPHAGY	degrades	entity	0.95
HYPOXIA	activates	entity	0.90
Autophagy	degrades	process	0.90
h-84808267	targets	hypothesis	0.90
Hypoxia	activates	process	0.85
Autophagy	downregulates	process	0.85
autophagy	degrades	process	0.80
Hypoxia	upregulates	process	0.80
HSPA8	degrades	gene	0.80
ABCB1	interacts_with	gene	0.65
LRP1	interacts_with	gene	0.65
TFR1	interacts_with	gene	0.65
KCNN3	associated_with	gene	0.60
GRIN2B	associated_with	gene	0.60
CACNA2D4	inhibits	gene	0.60
HIF1A	activates	gene	0.60
MTOR	associated_with	gene	0.60
IGF2R	associated_with	gene	0.60
HSP90AA1	associated_with	gene	0.60
COMT	associated_with	gene	0.60
HSPA1A	associated_with	gene	0.60
LCAT	interacts_with	protein	0.60
TRAF4	interacts_with	protein	0.60
NEURON	regulates	gene	0.60
MITOCHONDRIA	associated_with	gene	0.60
AND	associated_with	gene	0.60
OCLN	activates	gene	0.60
BECN1	activates	gene	0.60
CLDN5	activates	gene	0.60
CALB1	associated_with	gene	0.60
BRAF	activates	gene	0.60
BRAF	biomarker_for	gene	0.60
ROS	activates	gene	0.60
STROKE	activates	gene	0.60
ALS	interacts_with	gene	0.60
ALZHEIMER	regulates	gene	0.60
HDAC	activates	gene	0.60
CANCER	causes	gene	0.60
AND	causes	gene	0.60
MITOCHONDRIAL DYSFUNCTION	associated_with	gene	0.60
AND	inhibits	gene	0.60
CANCER	interacts_with	gene	0.60
ERK1/2	activates	gene	0.60
GENES	regulates	gene	0.60
ALZHEIMER'S DISEASE	regulates	gene	0.60
RNA	activates	gene	0.60
AGING	contributes_to	gene	0.60
NEURODEGENERATION	contributes_to	gene	0.60
PARKINSON	contributes_to	gene	0.60
RNA	regulates	gene	0.60

Targeting Hypotheses (0)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
No targeting hypotheses

Mentioning Analyses (1)

Scientific analyses that reference this entity

Blood-brain barrier transport mechanisms for antibody therapeutics

neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.773

Experiments (0)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (1)

Multi-agent debates referencing this entity

Anti-amyloid antibodies (lecanemab, donanemab) have ~0.1% brain penetrance. Engi

closed · Rounds: 4 · Score: 0.91 · 2026-04-06

Related Research

Hypotheses and analyses mentioning CAV1 in their description or question text

No additional research found

CAV1

Understanding Entity Pages

Summary

Wiki Pages (4)

CAV1

CAV1 Protein

CAV1 (Caveolin 1)

CAVEOLIN-1 Protein (CAV1)

Pathway Diagram

Outgoing (367)

Incoming (136)

Targeting Hypotheses (0)

Mentioning Analyses (1)

Blood-brain barrier transport mechanisms for antibody therapeutics

Experiments (0)

Related Papers (0)

Debates (1)

Anti-amyloid antibodies (lecanemab, donanemab) have ~0.1% brain penetrance. Engi

Related Research